Eton Pharmaceuticals Future Growth
Future criteria checks 4/6
Eton Pharmaceuticals is forecast to grow earnings and revenue by 117.7% and 19.6% per annum respectively while EPS is expected to grow by 118.4% per annum.
Key information
117.7%
Earnings growth rate
118.4%
EPS growth rate
| Pharmaceuticals earnings growth | 23.9% |
| Revenue growth rate | 19.6% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 10 May 2024 |
Recent future growth updates
Recent updates
Subdued Growth No Barrier To Eton Pharmaceuticals, Inc. (NASDAQ:ETON) With Shares Advancing 40%
Jan 09
The Consensus EPS Estimates For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Just Fell A Lot
Dec 13Eton Pharmaceuticals' (NASDAQ:ETON) Earnings May Just Be The Starting Point
Nov 16Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Despite Losing Money
Sep 30Not Many Are Piling Into Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Yet As It Plummets 26%
Jul 25Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?
Jun 29Is Eton Pharmaceuticals (NASDAQ:ETON) Using Debt In A Risky Way?
Dec 22Eton Pharmaceuticals acquires FDA-approved rare disease product betaine anhydrous
Sep 13Eton Pharmaceuticals: An Evolving 'Sum Of The Parts' Story
Aug 14Eton Pharma jumps 20% on FDA approval of seizure therapy
Jul 18Broker Revenue Forecasts For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Are Surging Higher
Apr 15Eton Pharmaceuticals (NASDAQ:ETON) Is Using Debt Safely
Oct 14Another Look At Eton Pharmaceuticals
Sep 03What Does The Future Hold For Eton Pharmaceuticals, Inc. (NASDAQ:ETON)? These Analysts Have Been Cutting Their Estimates
Aug 18Eton Pharma wins FDA approval for Rezipres
Jun 15FDA declines to approve Eton Pharmaceuticals' methanol poisoning treatment
May 28Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Is About To Turn The Corner
May 15Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?
Apr 05Could The Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Ownership Structure Tell Us Something Useful?
Mar 01Eton Pharma buys Canadian rights for Alkindi Sprinkle
Jan 14Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Shift From Loss To Profit
Jan 07
FDA accepts Eton application for Topiramate for partial seizures
Dec 17Eton Pharmaceuticals announces availability of ALKINDI SPRINKLE in U.S.
Nov 24Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 47 | 7 | 12 | 12 | 1 |
| 12/31/2024 | 36 | -2 | 1 | 1 | 1 |
| 3/31/2024 | 34 | 1 | 3 | 6 | N/A |
| 12/31/2023 | 32 | -1 | 6 | 7 | N/A |
| 9/30/2023 | 33 | 2 | 9 | 9 | N/A |
| 6/30/2023 | 29 | 0 | 5 | 7 | N/A |
| 3/31/2023 | 24 | -6 | -1 | 2 | N/A |
| 12/31/2022 | 21 | -9 | 2 | 5 | N/A |
| 9/30/2022 | 19 | -9 | -9 | -3 | N/A |
| 6/30/2022 | 16 | -12 | -8 | -4 | N/A |
| 3/31/2022 | 12 | -12 | -10 | -7 | N/A |
| 12/31/2021 | 22 | -2 | -8 | -5 | N/A |
| 9/30/2021 | 16 | -11 | -7 | -7 | N/A |
| 6/30/2021 | 15 | -11 | -9 | -9 | N/A |
| 3/31/2021 | 12 | -14 | -11 | -11 | N/A |
| 12/31/2020 | 0 | -28 | -22 | -22 | N/A |
| 9/30/2020 | 0 | -23 | -20 | -19 | N/A |
| 6/30/2020 | 1 | -21 | -18 | -17 | N/A |
| 3/31/2020 | 1 | -20 | -20 | -18 | N/A |
| 12/31/2019 | 1 | -18 | -20 | -18 | N/A |
| 9/30/2019 | 1 | -42 | -17 | -16 | N/A |
| 6/30/2019 | 1 | -40 | -16 | -15 | N/A |
| 3/31/2019 | 1 | -41 | -14 | -13 | N/A |
| 12/31/2018 | N/A | -37 | -8 | -8 | N/A |
| 9/30/2018 | N/A | -18 | -10 | -10 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ETON's forecast earnings growth (117.7% per year) is above the savings rate (2.4%).
Earnings vs Market: ETON's earnings (117.7% per year) are forecast to grow faster than the US market (14.6% per year).
High Growth Earnings: ETON's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ETON's revenue (19.6% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: ETON's revenue (19.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ETON's Return on Equity is forecast to be high in 3 years time